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relationship between RMU and migraine symptom end points was also assessed.
RESULTS: This post hoc analysis included 794 patients randomized (1:1) to receive
double-blind treatment with MAP0004 or placebo. The primary results of the study
were previously published. Patients were well matched for demographic and base-
line characteristics. Patients receiving MAP0004 experienced statistically signifi-
cantmigraine symptom reduction comparedwith patients receiving placebo. RMU
in the double-blind periodwas consistently lower withMAP0004 thanwith placebo
at 2 hours (4% vs. 8%, P0.0261), 4 hours (19% vs 37%, P0.0001), 24 hours (36% vs.
54%, P0.0001), and 48 hours (42% vs. 59%, P0.0001) after study-drug administra-
tion. RMU was also significantly lower with MAP0004 than with placebo across
demographic and baseline characteristics. Among patients who reported pain re-
lief at 2 hours, MAP0004-treated patients had significantly lower RMU at 4, 24, and
48 hours than placebo-treated patients. The overall adverse event rate was com-
parable to that of placebo. CONCLUSIONS: In this study, RMU was significantly
lower with MAP0004 than with placebo overall and across demographic and base-
line characteristics.
PND48
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OBJECTIVES: To profile real world treatment patterns of patients with tuberous
sclerosis complex (TSC) which is a genetic disease that can affect multiple organ
systems in the body.METHODS:We conducted a retrospective cohort study with a
large national healthcare claims database that consists of 39 million commercially
insured Americans between 2000 and 2009. Patients with a TSC claim and contin-
uous enrollment 12 months before and 12 months after their first TSC diagnosis
were included in the study (these selection criteria lead to the exclusion of those at
age less than one). Resource utilization rates (measured as number of claims per
patient) were examined for different provider types and places of services, and
compared between the year before and after the first TSC diagnosis. Two-tail
paired sample dependent t test and Chi-square test were used for pre-post com-
parisons as well as cross-region comparison. RESULTS: The included patients
(N1249) had a mean age of 33.9 years at their first TSC diagnosis, and 57.5% were
female. Resource utilization rates with significant pre-post differences were inpa-
tient admissions (0.16 vs. 0.08, p0.01), emergency care (1.14 vs. 0.78, p0.05),
hospital outpatient care (12.68 vs. 6.66, p0.05), neurologist care (0.60 vs. 0.32,
p0.05), neurological surgeon care (0.06 vs. 0.02, p0.05), oncologist care (0.32 vs.
0.12, p0.05), and the use of anti-epilepsy medications (2.45 vs. 2.10, p0.05). The
most common places of care were physician offices (21.44), hospital outpatient
departments (12.68) and specialty care facilities (8.37); the most common provider
specialties were primary care providers (6.07), neurologists (0.60), oncologists
(0.32), surgeons (0.29); and the most common class of medications were anti-epi-
lepsymedications (2.45). Significant cross-region variations in TSCmedication uti-
lization and costs were also observed (p0.05). CONCLUSIONS: TSC patients had a
very diverse treatment profile due to its multi-organ involvement. Future research
is needed to explore the driving forces behind cross-region variations in TSC treat-
ment.
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TREATMENT FOR PATIENTS DIAGNOSED WITH PARKINSON’S DISEASE:
DIFFERENCES BASED UPON DIAGNOSING PHYSICIAN
Lage MJ1, Grubb E2
1HealthMetrics Outcomes Research, Delray Beach, FL, USA, 2Teva Pharmaceuticals, Kansas City,
MO, USA
OBJECTIVES:To investigate Parkinson’s disease (PD)medication initiation patterns
based upon diagnosing physician specialty. METHODS: Data were obtained from
the i3 InVision™ Data Mart database from January 1, 2006 through March 30, 2011.
Patients included in the analyses were diagnosed with PD (initial diagnosis identi-
fied as index date) and had continuous insurance coverage from 6 months prior
through 12 months post index date, and were at least age 35. Categorical variables
were examined using chi-square statistics while continuous variables were exam-
ined using t-tests; all are descriptive. RESULTS:A total of 5967 patients fit the study
criteria. Patients diagnosed by a neurologist (N3173), compared to those diag-
nosed by another physician specialty, were more likely to be male (58.86% vs.
53.72%; P0.0002), younger (66.53 years vs. 70.81 years; P0.0001), and in better
health, as proxied by the Charlson Comorbidity Index (1.14 vs. 1.28; P0.0034).
Patients diagnosed by a neurologist were significantly more likely to be treated
with a PD medication during the study period (48.91% vs. 30.06%; P0.0001). A
neurologist was significantly more likely to initially prescribe a monoamine
oxidase B inhibitor (MAO-B) (21.07% vs. 12.86%; P0.0001) or carbidopa/
levodopa/entacapone (9.86% vs. 6.43%; P0.0004), than a physician of another
specialty, but significantly less likely to initially prescribe carbidopa/levodopa
(27.90% vs. 42.38%; P0.0001). There was no difference in the rates of switching
from initial class of PD medication or adjunctive use of an additional class of PD
medication, although among patients prescribed multiple classes of PD medi-
cations, patients diagnosed by a neurologist were more likely to be prescribed a
dopamine agonist in combination with a MAO-B (40.08% vs. 27.34%; P0.0147).
CONCLUSIONS: These analyses found differences in treatment patterns based
upon the specialty of the diagnosing physician. Additional studies are war-
ranted to raise awareness of differences in PD treatment by diagnosing physi-
cian and to address potential health care disparities.
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OBJECTIVES: Evaluate diagnosis and treatment initiation patterns in Parkinson’s
disease (PD) based upon age. METHODS: Data were obtained from the i3 InVi-
sionTM Data Mart database from January 1, 2006 through March 30, 2011. Patients
were diagnosed with PD (initial diagnosis identified as index date), had continuous
insurance coverage from 6 months prior through 12 months post index date and
were at least 35 years old. Cohorts were divided into those under 65 and over 65
years of age. These analyses are descriptive, with continuous variables examined
using t-tests and categorical variables examined using chi-square statistics.
RESULTS: A total of 5,967 patients fit the inclusion criteria. More individuals
(58.22%) were age 65 or older, and in worse physical health, evidenced by a signif-
icantly higher pre-period Charlson score (1.52 vs. 0.77; P0.0001) and had higher
rates of pre-period cerebrovascular disease (21.53% vs. 9.07%; P0.0001), cardiovas-
cular disease (22.86% vs. 8.10%; P0.0001), dementia (10.22% vs. 1.60%; P0.0001),
diabetes (22.77% vs. 14.64%; P0.0001), hypertension (56.99% vs. 35.10%; P0.0001),
and psychoses (15.03% vs. 9.51%; P0.0001). Individuals age 65were significantly
less likely to be treatedwith PDmedication (35.69% vs. 46.21%; P0.0001), andmore
likely to be diagnosed by a neurologist (61.37% vs. 48.29%; P0.0001). Older individ-
uals were more likely to be initially prescribed carbidopa/levodopa (44.27% vs.
20.83%; P0.0001), a catechol o-methyltransferase inhibitor (5.08% vs. 2.25%;
P0.0003), or carbidopa/levodopa/entacapone (10.81% vs. 6.34%; P0.0001), but sig-
nificantly less likely to be initially prescribed a dopamine agonist (32.42% vs.
47.14%; P0.0001), amonamine oxidase B inhibitor (12.50%vs. 24.31%; P0.0001), or
an anticholinergic (3.31% vs. 6.83%; P0.0001). There was no significant difference
between rates of switching from initially prescribedmedication (18.63% vs. 21.53%;
P0.0767), although younger individuals were more likely to add an additional
class of therapy (18.40% vs. 13.15%; P0.0004). CONCLUSIONS: These analyses
highlighted potential age disparities in treatment patterns.
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OBJECTIVES: To evaluate diagnosis and treatment initiation patterns in Parkin-
son’s disease (PD) based upon patient sex.METHODS:Data used for these analyses
were obtained from the i3 InVisionTM Data Mart database from January 1, 2006
through March 30, 2011. Patients were included in the analyses if they were diag-
nosedwith PD (initial diagnosis identified as index date) had continuous insurance
coverage from6months prior through 12months post index date, andwere at least
35 years old. The analyses are descriptive, with differences in continuous variables
examined using t-tests and differences in categorical variables examined using
chi-square statistics. RESULTS: A total 5967 patients who fit the inclusion and
exclusion criteria. Results revealed significant differences based on sex. More men
(56.29%) than women were diagnosed with PD, and men were in worse overall
physical health as evidenced by a significantly higher pre-period Charlson score
(1.10 vs. 1.29; P0.0001) and higher rates of pre-period diagnoses of cardiovascular
disease (21.05% vs. 11.08%; P0.0001), diabetes (20.06% vs. 17.71%; P0.0043), and
high cholesterol (38.67% vs. 34.05%; P0.0002). Female patients, however, were
more likely to be diagnosed with mental-health comorbidities, such as anxiety
(8.93% vs. 5.45%; P0.0001), depression (16.53% vs. 11.34%; P0.0001), or psychoses
(14.46% vs. 11.37%; P0.0004). Males were significantly more likely to receive PD
medication (43.55% vs. 35.68%; P0.0001) and were more likely to be diagnosed by
a neurologist (55.31% vs. 50.42%; P0.0008). Maleswere also found to bemore likely
to be initially prescribed a monamine oxidase B inhibitor (20.16% vs. 15.07%;
P0.0016). There was no significant difference between males and females with
regards to rates of switching from initially prescribed medication (20.37% vs.
19.48%; P0.5978) or adding an additional therapy to their initial regime (16.47% vs.
14.42%; P0.1792). CONCLUSIONS: These analyses highlight potential sex dispar-
ities in treatment patterns.
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OBJECTIVES: The objective of this study was to determine if an association existed
between race/ethnicity and exposure to Alzheimer’s disease (AD) pharmacother-
apy across four state Medicaid populations. METHODS: Data from the Centers for
Medicare and Medicaid services was used in this retrospective study. Individuals
had to have an AD diagnosis (ICD-9 code 331.0) and be enrolled in a California,
Florida, New Jersey, or New York Medicaid program during 2004. Outcomes of
interest were exposure to a cholinesterase inhibitor (ChEI) or memantine. Multi-
variate logistic regression was used to test for the association between race/eth-
nicity and the exposure to a ChEI or memantine. Variables of interest included
demographic characteristics and resource utilization factors. The Oaxaca-Blinder
decomposition method to test for disparities was used to determine if exposure to
a ChEI or memantine was influenced by race. RESULTS: Approximately 158,974
individuals qualified for this study. Race, age, long-term care admittance, inpatient
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care admittance, Charlson co-morbidity score, state of residence, and gender all
were significant predictors of AD medication use (p  0.0001 for all variables).
Racial/ethnic disparities were observed with respect to exposure to a ChEI or me-
mantine between Non-Hispanic Whites and Hispanics (in favor of Hispanics) in
California (p  0.002) and Florida (p  0.0001), between Non-Hispanic Whites and
Non-Hispanic Others (in favor of Non-Hispanics Others) across all states, between
Non-Hispanic Blacks andNon-Hispanic Others (in favor of Non-Hispanic Others) in
California (p  0.0001) and New York (p  0.0001), and between Hispanics and
Non-Hispanic Others (in favor of Non-Hispanic Others) in California (p  0.001),
Florida (p  0.013), and New York (p  0.0001). CONCLUSIONS: Disparities in AD
medication use among minority-to-minority populations are just as prevalent, if
not higher, than minority-white disparities. Furthermore, geographical location
was important predictor of health disparities.
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OBJECTIVES: Epilepsy has been the focus of several primary care programs across
LatinAmerica region due to its high prevalence and related burden. Hospitalization
could be used as an indicator for frequency ofmore severe cases with uncontrolled
and frequent seizures. Thus, hospital admission trends could be instrumental to
understanding treatment gaps and support decision making. Our objective was to
evaluate hospital admission trend by Epilepsy in three Latin America Countries.
METHODS: Hospitalization data were extracted from Public Healthcare Databases
from Brazil, Chile and Mexico covering 2001-2008. Country and age-specific hospi-
tal admission frequencies due to Epilepsy (ICD G40) in people 14 years-old were
calculated. Three age range categories were created: 15-29; 30-44; 45-59 and 60.
We built general estimating equation models with Poisson distributions to evalu-
ate hospital admissions time trends. Further, the differences between the age
ranges were also estimated. RESULTS:Means of annual hospitalization rates were
similar in Brazil and Chile (2.63 and 2.79, respectively) but comparatively low in
Mexico (0.39). The three countries showed different in-hospital patterns over time.
Brazil had a downward tendency with an annual ratio of 0.982 (p0.001) and Chile
a relatively flat one (pNS). On the other hand, Mexico presented an upward trend,
with an annual ratio of 1.043 (p0.001). Mean hospitalization rates were higher in
older age categories in Brazil and Chile and the younger ones in Mexico. The age
categories were following the trends showed by their respective countries in the
overall analysis. CONCLUSIONS: Despite having qualitatively similar assistance
programs across the region, the countries showed different rates and patterns of
hospitalization due to Epilepsy. Direct comparison between countries should be
examined cautiously due to important differences in their health care systems and
data collection process.
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OBJECTIVES: To compare short and long-term all cause health care resource utili-
zation among newly diagnosed multiple sclerosis (MS) patients enrolled in Man-
aged Medicaid or Commercial health plans. METHODS: We used the I3 InVision
Data Mart to identify continuously enrolled patients 18 years of age with at least
two ICD-9 codes for multiples sclerosis (340.xx) between the dates of June 1, 2006
and March 31, 2010. Baseline patient characteristics as well as thirty-day and 24
month all cause health care resource utilization and costs were assessed using
Analysis of Variance (ANOVA) for continuous variables and Chi-squared statistics
for continuous variables.RESULTS:Medicaid beneficiariesweremore likely to have
more psycho-social limitations (23.5%; p 0.0001) than their counterparts insured
through commercial plans. Within the first 30 days of diagnosis, Medicaid HMO
beneficiaries were more likely to be hospitalized (p  0.006) and utilize Emergency
Department services (p  0.0001). In addition, Medicaid HMO beneficiaries were
20% less likely to have a claim for a Neurologist vist and 50% less likely to be
prescribed disease modifying therapies than commercial enrollees. Long-term ac-
cess tomedical servicesmirrored that observed in the short termwith higher rates
of hospitalization (p  0.006) and emergency department use (p  0.001) and less
access to Neurologist (p  0.001) and disease modifying treatment (p  0.027).
CONCLUSIONS: Opportunities exist to support newly diagnosed MS patients en-
rolled inMedicaidHMOplans. The development and implementation of innovative
managed care strategies will ensure that Medicaid HMO beneficiaries received ac-
cess to specialty care and approved treatments at the same rate as their counter-
parts enrolled in commercial health plans.
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OBJECTIVES: The study examined determinants of prescription drug expenditures
in patients with Multiple Sclerosis (MS) in United States (US). METHODS: Retro-
spective cross-sectional study was conducted using the 2002-2009 Medical Expen-
diture Panel Survey (MEPS) data, a nationally representative data on the commu-
nity dwelling, non-institutionalized US population. The study sample included
patients diagnosed with MS (ICD-9-CM: 340). Weighted descriptive statistics were
performed to estimate the total and prescription drug expenditures. Multiple Or-
dinary Least Square regression analysis within the conceptual framework of An-
derson Behavioral Model was performed to identify factors associated with pre-
scription drug expenditures. The log transformation of the prescription drug
expenditures was carried out to address skewed nature of cost data. RESULTS: An
estimated of 4.1 million patients were diagnosed with MS during 2002-2009. The
total average expenditure for MS patients was $17,619 (95% CI: 16,385-18,913). Of
which 44%was attributable to the prescription drugs cost, i.e. $7760 (95% CI: 7169 –
8350). The linear regression revealed that predisposing (region), enabling (health
insurance coverage) and need (charlson comorbidity score) factors were signifi-
cantly associated with prescription drug expenditures. Patients from the Midwest
region had 65% higher prescription expenditure than the west region patients.
Patients with public insurance had 164% higher prescription expenditures than
uninsured patients. One unit increase in charlson comorbidity score was associ-
ated with 28% higher prescription drug expenditure. CONCLUSIONS: The total
prescription drug expenditures accounted for nearly half of total medical expen-
diture in patients with multiple sclerosis. In addition to need factors, the predis-
posing and enabling factors played an important role in influencing prescription
drug expenditures in patients with multiple sclerosis.
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OBJECTIVES: The objective of this research is to understand emerging value per-
ceptions of novel treatments in Multiple Sclerosis from the perspective of US Man-
aged Care Organization decision makers and prescribing physicians. METHODS:
Explorative primary research interviews (n35) were conducted with a sample of
Managed Care Organization decision makers, practicing neurologists, hospital
pharmacy directors, and specialty pharmacy distribution managers. The sample
was composed of national and regional payers representing various patient popu-
lations with commercial or government-funded coverage. Interviews were con-
ducted from April to June 2011 and consisted of individual one-hour phone inter-
views. Survey questions were focused on identifying payer perceptions of unmet
need in current Multiple Sclerosis (MS) disease management, payer and physician
reactions to the first oral treatment entrant (Gilenya), and projections for changes
in treatment algorithms and benefit design upon availability of additional oral
therapies. Qualitative surveymethods for eliciting stated preferences for formulary
management decisions were used. RESULTS: Payers and physicians described the
unmet need in MS treatment being driven by the absence of optimal disease-
modifying treatments and evidence correlating available treatments to long-term
outcomes. Payers are sensitive to recent price increases in the category and man-
agement practices in MSmay becomemore aggressive in the near-term as compe-
tition for value increases. Payers and physicians anticipate future oral treatments
in development to induce increased in oral drug initiation but do not anticipate
rapid conversion from injectable therapy to oral therapy. CONCLUSIONS: Payers
and prescribers acknowledge oral therapy options for MS as an expansion in treat-
ment options offering more convenient administration. Rising cost of therapy and
evidence of long-term outcome improvement with their utilization remain con-
cerns in supporting the value of these treatments.
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BACKGROUND: US payers often employ a fail-first approach to multiple sclerosis
(MS), imposing multiple steps through therapies as patients relapse, progress and
accumulate disability. However, within the past year, one managed care organiza-
tion has piloted an outcomes-based contract in MS. Tier status and discounts will
be tied to medication adherence, avoidance of relapses and subsequent hospital-
izations. At the same time, the MS therapy pipeline is rapidly evolving, and may
offer opportunities for contracting based on volume, or a portfolio of products for
multiple lines of therapy.OBJECTIVES: To gauge the level of interest among payers
in piloting value-based insurance designs (VBID) for oral and intravenous therapies
in MS. Additionally, to identify characteristics of plans most likely to implement
VBID; and to highlight implications for development of real-world outcomes data
to support innovative contracting. METHODS: Pharmacy and medical directors of
managed care payers will be asked to rate their level of interest in different benefit
designs for oral and intravenous MS therapies. Benefit designs include integrated
medical/pharmacy benefits; open access plans; pathways based on futility rules;
outcomes-based contracting; and risk-sharing tied to avoidance of hospitaliza-
tions. The interview sample will include a mix of plans with different approaches
to use of specialty pharmacy in MS and additional management practices.
RESULTS: Critical success factors for VBID (such as ability to link datasets from
pharmacy and medical claims) will be identified. In addition, specific outcomes
required to design or implement VBID, such as impact of time on ineffective ther-
apy and/ormedication non-adherence, will be prioritized based on payer feedback.
Lastly,metrics for demonstrating return on investment fromVBID inMS, including
PMPM as well as drug budget impact and medical cost offsets, will be elucidated.
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